If you have been reading about LC-MS/MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
=== Exoenzymes === Exoenzymes are enzymes secreted by microorganisms, such as bacteria and fungi, to function outside their cells. These enzymes are crucial for breaking down large molecules in the environment into smaller ones that the microorganisms can absorb (transport into their cells) and use for growth and energy. Several studies have demonstrated that the activity of extracellular enzymes in aquatic microbial ecology is of algal origin. These exoenzymes released from microalgae include alkaline phosphatases, chitinases, β-d-glucosidases, proteases etc. and can influence the growth of microorganisms, chemical signaling, and biogeochemical cycling in ecosystems. The study of these exoenzymes may help to optimize the nutrient supplement strategy in aquaculture. Nevertheless, only a few of the enzymes were isolated and purified. Selected prominent enzyme classes are highlighted in the cited literature.
== Impacts by region == Observations of ENSO events since 1950 show that impacts associated with such events depend on the time of year. While some events and impacts are expected to occur, it is not certain that they will happen. The impacts that generally do occur during most El Niño events include below-average rainfall over Indonesia and northern South America, and above average rainfall in southeastern South America, eastern equatorial Africa, and the southern United States.
In the US, Aducanumab is indicated for the treatment of Alzheimer's disease. In July 2021, the US Food and Drug Administration (FDA) limited the indication to people with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. Aducanumab is a monoclonal IgG1 antibody that binds to the amyloid beta protein at amino acids 3–7, which is posited to result in slowing the progression of Alzheimer's disease. The mechanism is based on the amyloid hypothesis, which posits that amyloid proteins cause Alzheimer's disease, hence removing amyloid should slow the progression of the disease. How the antibody accesses the plaques is under active research. One mechanism suggests the plaques are exposed to the lumen of blood vessels and the antibody accesses the plaques from the lumen side. This assumes the plaque formed as a result of a leaky blood brain barrier and may also explain why there is hemorrhage after the plaques are removed. The most common serious adverse reactions reported are:
Ozioma Akagha () is an American actress. She voices Alyx Vance in the video game Half-Life: Alyx (2020) and Julianna in the video game Deathloop (2021). She also plays the role of Harper Omereoha in the television show Delilah.
Sources: en.wikipedia.org
RU-24213, also known as 3-hydroxy-N-propyl-N-(phenylethyl)phenethylamine, is a dopamine receptor agonist of the phenethylamine family related to dopamine. It is a selective dopamine D2-like receptor agonist. Subsequently, however, RU-24213 was found to also act as a potent κ-opioid receptor (KOR) antagonist. It led to the development of the diphenylethylamine series of KOR ligands. RU-24213 was first described in the scientific literature in 1978.
Pain and stiffness (moderate to severe) in the neck, shoulders, upper arms, thighs, and hips, which inhibits activity, especially in the morning, but which usually persists to some degree throughout the day. Pain can also occur in the groin area and in the buttocks. The pain can be limited to one of these areas as well. It is a disease of the "girdles" meaning shoulder girdle or pelvic girdle. Fatigue and lack of appetite (possibly leading to weight loss) Anemia An overall feeling of illness or flu-like symptoms. Low-grade (mild) fever or abnormal temperature is sometimes present. High or spiking fevers may occur in patients who also have giant cell arteritis. Generalized weakness Note that this is generalized weakness, not muscle weakness. The presence of muscle weakness likely indicates a different diagnosis. Inflammatory swelling and pain of wrists and/or knees (only ~25% of cases) Pitting edema (non-inflammatory swelling) of wrists, ankles, hands, and feet (only ~10% of cases)
== History == Bodybuilding.com grew out of wholesale-creatine.com, an online storefront created by teenage web marketer and amateur bodybuilder Ryan DeLuca in 1997, to capitalize on the rising popularity of creatine supplements. A majority stake in Bodybuilding.com was acquired in July 2006 by Milestone Partners for an undisclosed amount. In 2007, an FDA agent purchased several supplements from Bodybuilding.com which were determined to contain anabolic steroids. In May 2012, the company was fined $7 million, and as part of the settlement, CEO DeLuca and his brother Jeremy were both fined $600,000 for selling misbranded drugs. In January 2008, Liberty Media Corporation acquired a controlling stake in Bodybuilding.com for more than $100 million. DeLuca stayed on as the company's CEO.
=== Subsequent history === In 2008, SPUSA candidate for President Brian Moore vocally opposed the idea that Barack Obama was a socialist of any kind, saying it was "misleading of the Republicans" to spread that message. In 2009, the Socialist Party of Connecticut protested in Hartford against Obama's troop surge in Afghanistan. In 2010, SPUSA Co-Chair Billy Wharton called Obama's 2010 State of the Union Address a "public relations ploy". Wharton criticized the Affordable Care Act as designed "to protect the profit margins of private insurance companies". In 2012, SPUSA member Pat Noble was elected to the Red Bank Regional High School Board of Education. Noble ran openly as a Socialist, despite the race being nonpartisan.
=== Brittleness === Most salts are very brittle. Once they reach the limit of their strength, they cannot deform malleably, because the strict alignment of positive and negative ions must be maintained. Instead the material undergoes fracture via cleavage. As the temperature is elevated (usually close to the melting point) a ductile–brittle transition occurs, and plastic flow becomes possible by the motion of dislocations.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.